This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gordon, M. S. Search for Related Content PubMed PubMed Citation Articles by Gordon, M. S.

Managing Anemia in the Cancer Patient: Old Problems, Future Solutions

Arizona Health Sciences Center, University of Arizona, Phoenix, Arizona, USA

Correspondence: Michael S. Gordon, M.D., Office of Research, Arizona Health Sciences Center, University of Arizona, 4001 North 3rd Street, Suite 415, Phoenix, Arizona 85012, USA. Telephone: 602-631-4610; Fax: 602-631-4611; e-mail: msgordon{at}u.arizona.edu

Anemia and associated symptoms commonly manifest in cancer patients and may have a considerable impact on outcomes. Preliminary studies suggest that overall survival and locoregional control following radiation therapy may be compromised by anemia, and recent preliminary data also suggest that anemia may be related to poorer outcomes following chemotherapy. Health-related quality of life of cancer patients is also significantly reduced by anemia. Treatment of anemia with recombinant human erythropoietin can improve these health-related quality-of-life outcomes. However, despite this knowledge, anemia remains under-recognized and under-treated in the cancer patient population. A number of issues may be determinants of this suboptimal management of anemia. These include limitations of current therapies for anemia, varying practice strategies, and the lack of guidelines on how to treat anemia. Additionally, clinicians may underestimate the importance of health-related quality of life for their patients. It is vital that these issues are addressed, which, together with the development of novel erythropoietic agents, a review of the guidelines for anemia management, and consideration of further outcomes such as survival and cognitive function, may help to ensure that the cancer patient receives the best possible course of supportive care.

Key Words. Anemia • Cancer • Survival • Quality of life • Recombinant human erythropoietin • Darbepoetin alfa

This article has been cited by other articles:

				R. E. Smith Jr, M. S. Aapro, H. Ludwig, T. Pinter, M. Smakal, T. E. Ciuleanu, L. Chen, T. Lillie, and J. A. Glaspy Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Clin. Oncol., March 1, 2008; 26(7): 1040 - 1050. [Abstract] [Full Text] [PDF]

				B. Kralj, D. Iverson, K. Hotz, and F. D. Ashbury The Impact of Computerized Clinical Reminders on Physician Prescribing Behavior: Evidence From Community Oncology Practice American Journal of Medical Quality, September 1, 2003; 18(5): 197 - 203. [Abstract] [PDF]